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Identiﬁcation of disease-linked hyperactivating
mutations in UBE3A through large-scale functional
variant analysis
1234567890():,;

Kellan P. Weston1,9, Xiaoyi Gao1,9, Jinghan Zhao 1, Kwang-Soo Kim1, Susan E. Maloney2, Jill Gotoff3,
Sumit Parikh4, Yen-Chen Leu5, Kuen-Phon Wu 5, Marwan Shinawi 6, Joshua P. Steimel7,
Joseph S. Harrison8 & Jason J. Yi 1 ✉

The mechanisms that underlie the extensive phenotypic diversity in genetic disorders are
poorly understood. Here, we develop a large-scale assay to characterize the functional
valence (gain or loss-of-function) of missense variants identiﬁed in UBE3A, the gene whose
loss-of-function causes the neurodevelopmental disorder Angelman syndrome. We identify
numerous gain-of-function variants including a hyperactivating Q588E mutation that strikingly increases UBE3A activity above wild-type UBE3A levels. Mice carrying the Q588E
mutation exhibit aberrant early-life motor and communication deﬁcits, and individuals possessing hyperactivating UBE3A variants exhibit affected phenotypes that are distinguishable
from Angelman syndrome. Additional structure-function analysis reveals that Q588 forms a
regulatory site in UBE3A that is conserved among HECT domain ubiquitin ligases and perturbed in various neurodevelopmental disorders. Together, our study indicates that excessive
UBE3A activity increases the risk for neurodevelopmental pathology and suggests that
functional variant analysis can help delineate mechanistic subtypes in monogenic disorders.
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T

he identiﬁcation of genes linked to human disorders traditionally focuses on lesions that can be interpreted easily
as reducing gene function. Although this method has been
effective in establishing causality, a simple loss-of-function model
is insufﬁcient to account for the broad phenotypic heterogeneity
observed in many neurodevelopmental disorders. This is especially important for the millions of uncharacterized coding variants identiﬁed in the human genome1,2, some of which represent
pathogenic mutations that may bi-directionally alter the functional valence of a protein (loss or gain-of-function). However,
the clinical signiﬁcance for the vast majority of known variants
remains undetermined3, representing an immensely understudied
area of human genetics.
UBE3A encodes an E3 ubiquitin ligase that promotes the
proteasomal degradation of proteins4. Abnormal changes in
UBE3A activity are associated with various human conditions
including human papilloma virus-mediated cancer4 and neurodevelopmental disorders. In neurons, UBE3A expression is epigenetically modiﬁed such that transcription of paternal UBE3A is
silenced and only the maternally-inherited copy is expressed5–7. It
is well established that loss of maternal UBE3A causes Angelman
syndrome (AS), a severe form of intellectual disability characterized by epilepsy, motor deﬁcits, dysmorphic facial features,
and a unique happy demeanor8–10. In contrast, excessive UBE3A
activity resulting from duplication of maternal chromosome
15q11-13, the region where UBE3A resides, is linked to an autistic
disorder known as Dup15q syndrome11. However, there are only
two known examples that speciﬁcally link UBE3A gain-offunction to neurodevelopmental disease. This includes one de
novo hyperactivating missense mutation identiﬁed in a child with
autism12,13, and a microduplication of UBE3A that segregates
with neuropsychiatric phenotypes in one family14. These limited
observations have raised questions about the extent to which
excessive UBE3A activity contributes to neurodevelopmental
pathology.
UBE3A belongs to the HECT (Homologous to E6-AP C-terminus) domain superfamily of E3 ubiquitin ligases which are
implicated in an array of human conditions15. They all possess
the eponymous HECT domain which houses the biochemical
machinery necessary to accept activated ubiquitin from E2
enzyme, and transfers it to substrate proteins. In previous work,
we and others found that UBE3A activates WNT reporter gene
expression in HEK293T cells in a manner that is dependent on its
ubiquitin ligase activity16–19.
Here, we used this insight to quantitatively assess the functional signiﬁcance of 152 UBE3A variants identiﬁed in individuals. We discovered many mutations that impact UBE3A
activity, including 18 hyperactivating mutations. By generating
a knock-in mouse model, we show that hyperactivation of
maternal, but not paternal UBE3A is sufﬁcient to perturb
neonatal motor behaviors and communication, and using
patient data, we show that UBE3A hyperactivity produces
phenotypes that are distinct from AS. Finally, using the rich
structure–function data derived from our screen, we uncovered
a conserved regulatory mechanism in UBE3A that is commonly
perturbed by both loss and gain-of-function mutations. Together, our results provide strong evidence that excessive UBE3A
activity increases the risk for neurodevelopmental pathology
and suggest that detailed functional variant analysis can provide
a widely-applicable method to identify mechanistic sub-classes
of genetic disorders.
Results
An efﬁcient cell-based screen to characterize UBE3A variant
function. There are hundreds of non-truncating UBE3A missense
2

variants contained in the Genome Aggregation (gnomAD v2.1.1)2
and ClinVar1 databases. Most variants are exceedingly rare
(average allele frequency <0.0001) and nearly two-thirds of variants in ClinVar have conﬂicting interpretations or are classiﬁed
as a variant of uncertain signiﬁcance (VUS; Fig. 1a). Moreover,
variants in UBE3A occur both inside and outside of known
functional domains, making it impossible to predict their functional signiﬁcance without empirical assessment (Fig. 1b).
We utilized the luciferase-based β-catenin activity reporter
(BAR)20, which is activated in a dose-dependent way by UBE3A
(Fig. 1c), to determine if it can accurately assess the activity of
UBE3A variants. We tested a variety of variants clinically and
functionally validated in previous studies12,21–29. Among these
were the benign variants R39H and A178T28,29, the autism-linked
hyperactivating mutation T485A12,13, as well as numerous ASlinked mutations known to cause loss-of-function through
various mechanisms12,21. We introduced mutations into a
plasmid encoding human UBE3A isoform 2 and measured the
BAR response in HEK293T cells. For every mutant, the BAR
assay correctly identiﬁed changes in the valence and severity of
the mutation in relation to wild type (WT) UBE3A (Fig. 1d).
Whereas the benign R39H (119.68% ± 21.3) and A178T
(97.45% ± 5.9) variants did not deviate from WT UBE3A activity
levels, the T485A mutant increased the BAR response
(189.02% ± 12.4) and all AS-linked loss-of-function mutations
exhibited diminished responses regardless of their mechanism of
dysfunction. This included constitutively self-targeting mutations
whose severity was demonstrated previously to be strong (T106P,
8.45% ± 1.8) and mild (T106K, 65.09% ± 5.1 and I130T,
76.31% ± 6.1), indicating that BAR responses can distinguish
the relative severity of UBE3A dysfunction12. Together, these
results demonstrate the utility of the BAR assay as a general and
accurate reporter of UBE3A activity across different mechanisms
that perturb enzyme function.
UBE3A variants deﬁne a broad landscape of functional effects.
We cloned nearly all of the UBE3A missense variants present in
the ClinVar database and assessed their effect on UBE3A activity
(Fig. 2a). Our library contained 152 variants in total, comprised of
133 amino acid substitutions, 18 in-frame deletions, and one inframe duplication. Whereas the activity of ~23% of variants did
not change from WT UBE3A, indicating they are likely benign,
we classiﬁed ~61% as strong loss-of-function mutations (≤50% of
WT UBE3A activity) and ~4% as weak loss-of-function mutations (>50% of WT UBE3A activity; Fig. 2b and Supplementary
Data 1). Surprisingly, our screen also found that ~9% of all variants are strong gain-of-function mutations (>150% of WT
UBE3A activity) while ~3% are weak gain-of-function mutations
(≤150% of WT UBE3A activity; Fig. 2b and Supplementary
Data 1).
Some of the variants tested in our screen disrupted residues in
domains known to be important for UBE3A function. One such
domain was an N-terminal zinc (Zn2+) ﬁnger known as the
AZUL domain (amino-terminal Zn-ﬁnger of UBE3A ligase) that
dictates UBE3A localization19,30,31. Six variants were located
within the AZUL domain including a loss-of-function mutation
that disrupts a Zn2+ chelating residue (C21Y, 1.07% ± 0.001 of
WT UBE3A activity) and the adjacent amino acid (G20V,
2.07% ± 0.79; Fig. 2c). Our screen also included variants in the E6
binding domain (E6BD; amino acids 378–396), a site where the
human papilloma virus (HPV) E6 protein binds to UBE3A4. Two
hyperactivating mutations were found within this region including a L390F mutation that elevated UBE3A activity
229.81% ± 9.33 above the WT BAR response (Fig. 2d), suggesting
the E6BD is an important regulator of UBE3A function even in
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Fig. 1 Genetic variation in UBE3A. a The distribution of clinical interpretations in ClinVar for missense variants identiﬁed in UBE3A. Blue: Benign/Likely
Benign, Red: Pathogenic/Likely Pathogenic, Gray: Uncertain/Conﬂicting. b Schematic showing human UBE3A with known functional domains. The number
of variants and their positions corresponding to the UBE3A protein sequence are shown. c Cultured cells were transfected with increasing amounts of
plasmid encoding WT UBE3A. Mean values are shown for Fireﬂy/Renilla ratios ± standard error (SE). N = 3 independent experiments. d BAR responses of
variants were normalized to WT UBE3A responses in each experiment. Values are shown as the mean ± SE. Each variant was tested in triplicate per
experiment and the resulting values averaged. The number of experiments performed (n) and p-values calculated using a one-sample t-test (two-tailed)
with Benjamini–Hochberg multiple comparisons correction (FDR = 0.05) are as follows: GFP, n = 19, ***p = 1.733 × 10−31; WT UBE3A, n = 19; UBE3A LD,
***p = 1.519 × 10−31, n = 19; R39H, n = 3, p = 0.567; A178T, n = 4, p = 0.828; T485A, n = 5, *p = 0.019; C21Y, n = 3, ***p = 8.725 × 10−6; C117R, n = 3,
***p = 3.419 × 10−4; N243K, n = 3, **p = 0.0072; E269G, n = 3, **p = 7.787 × 10−4; L273F, n = 3, **p = 0.0052; S349P, n = 3, **p = 0.0016; L502P, n = 3,
**p = 0.0033; R506C, n = 3, **p = 0.0033; T106K, n = 6, **p = 0.0.0078; T106P, n = 3, **p = 0.0013; I130T, n = 6, *p = 0.016; R477P, n = 3,
***p = 4.24 × 10−4; M478I, n = 3, ***p = 3.39 × 10−4; R482P, n = 3, **p = 5.82 × 10−4; I329T, n = 5, ***p = 1.22 × 10−5; E550L, n = 3, *p = 0.0013.

the absence of HPV E6. Finally, we identiﬁed a large number of
mutations in the HECT domain of UBE3A, including loss-offunction mutations in the E2 enzyme binding domain (T656I and
F690C)32, and loss-of-function mutations at the catalytic cysteine
(C820S and C820Y; Fig. 2e)33.
Our functional data correlated poorly to predictions for two in
silico programs used widely for variant interpretation34,35 (Supplementary Fig. 1a), demonstrating the necessity for empirical
assessment. A particularly interesting class of variants were
substitutions that occurred at the same amino acid position. There
were 18 such cases comprising a total of 39 variants tested in our
study (Fig. 2f). Some of these variants had consistent effects and
could be classiﬁed collectively as benign (R39C/H), loss-of-function
(T106K/P, L237H/P, L273R/F, M478V/I, R506C/H, G545R/E,
E550Δ/L/K, M566K/R, G738E/R, P815H/R, C820S/Y, and
P827L/S), or gain-of-function (R516Q/W). In contrast, asparagine
692 (N692) possessed a benign (N692H) and a weak gain-of-function
mutation (N692S) whereas valine 133 (V133) possessed a weak
gain-of-function (V133I) and strong loss-of-function mutation
(V133G). Moreover, glutamine 588 (Q588) and threonine 787
(T787) simultaneously possessed strong gain-of-function mutations
(Q588E and T787A/M) and strong loss-of-function (Q588P/R and
T787R) mutations (Fig. 2f).
We were particularly interested in this last class of mutations
because they exerted a disproportionally large and bi-directional
inﬂuence on UBE3A activity, suggesting that sites containing

hyperactivating mutations in general, are hyper-modulatory sites
that mediate the active and inactive states of UBE3A. To test this
hypothesis, we substituted every possible amino acid at leucine
781 (L781) and T787, two positions that contained the strongest
hyperactivating mutations in our screen (L781H and T787M;
Supplementary Fig. 1b). We anticipated that mutation of these
sites would produce multiple strong loss and gain-of-function
enzymes reﬂecting their central role in enzyme regulation.
Indeed, we found an extensive range of effects in our BAR assay
that spanned from 7.48 to 656.55% of WT UBE3A activity for
L781, and 1.33 to 1245.07% of WT UBE3A activity for T787
(Supplementary Fig. 1b and Supplementary Table 1). Taken
together, our analyses demonstrate that variants in UBE3A impart
highly heterogeneous effects to protein function and suggest that
sites of hyperactivating mutations signify amino acids that are
critical for UBE3A regulation.
Hyperactivating mutations alter UBE3A ubiquitin ligase
activity. To date, the UBE3A T485A mutation, which abolishes a
regulatory PKA phosphorylation site, is the only disease-linked
gain-of-function mutation reported for UBE3A12. Our analysis
identiﬁed 18 additional hyperactivating mutations (Fig. 3a) with
many exhibiting much higher activity than UBE3A T485A
(Fig. 3b). We sought to validate whether these variants represented a true gain-of-function of the ubiquitin ligase activity of
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Fig. 2 UBE3A variants encompass a broad landscape of functional effects. a BAR assay screen of 152 UBE3A variants showing benign (gray), weak lossof-function (light blue), strong loss-of-function (blue), weak gain-of-function (pink), and strong gain-of-function (red) mutations relative to WT UBE3A.
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structure (PDB: 4GIZ) of the E6BD domain of UBE3A (green) bound to HPV E6 (gold). Variants tested in our screen are shown in red. e Co-crystal
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UBE3A. Western blot analysis showed that all gain-of-function
mutants were present at comparable abundance or were less
abundant than WT UBE3A in HEK293T cells (Supplementary
Fig. 2a, b), indicating hyperactivity did not result from a simple
increase in enzyme levels. Moreover, when we introduced a
ligase-dead mutation (C820A) into each gain-of-function mutant,
there was a complete loss of the BAR response (Fig. 3c),
demonstrating that reporter activation resulted from increased
ubiquitin ligase activity.
We next tested the ability of gain-of-function mutants to selfubiquitinate, a process shown to be accelerated for the
hyperactive UBE3A T485A mutation12 as well as for a variety
of active HECT domain ubiquitin ligases36,37. We selected several
strong gain-of-function mutations in the HECT domain and
performed in vitro ubiquitination reactions using recombinant
proteins puriﬁed from bacterial cells. We found that mutant
proteins accelerated self-ubiquitination resulting in the formation
of higher molecular weight bands and the eventual loss of the
4

monomeric UBE3A band (Fig. 3d). This result was consistent in
HEK293T cells where gain-of-function mutants increased selfubiquitination compared to WT UBE3A (Supplementary Fig. 2c).
Finally, we measured the ability of gain-of-function mutants to
target a substrate protein for degradation in cells. We performed
this experiment with a ligase-inactive mutant of RING1B, a
polycomb repressor complex protein used widely as an in vitro
substrate of UBE3A38. Western blot analysis showed that whereas
RING1B abundance increased in the presence of ligase-dead
UBE3A (176% ± 0.13 relative to WT), every hyperactivating
mutation tested in our assay decreased RING1B protein levels.
Indeed, R516Q (67.48% ± 3.68), R516W (60.16% ± 4.63), A521T
(55.16% ± 4.71), Q588E (60.58% ± 4.44), L781H (52.31% ± 4.30),
T787A (52.96% ± 6.31), and T787M (52.37% ± 4.91) all reduced
RING1B abundance to a fraction of WT UBE3A levels
(Supplementary Fig. 2d, e). Collectively, these results provide
direct evidence that gain-of-function mutations identiﬁed in our
study elevate the ubiquitin ligase activity of UBE3A.
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R516Q LD, ***p = 1.55 × 10−5; R516W LD, ***p = 1.59 × 10−4; A521T LD, **p = 0.0014; Q588E LD, ***p = 1.25 × 10−4; N692S, ***p = 1.37 × 10−5; K701I,
***p = 1.37 × 10−5; L726Δ LD, ***p = 1.02 × 10−4; G755S LD, ***p = 6.25 × 10−5; R780S LD, ***p = 8.68 × 10−6; L781H LD, ***p = 1.44 × 10−4; T787A LD,
***p = 1.36 × 10−6; T787M LD, ***p = 1.25 × 10−8. d In vitro ubiquitination assay was performed using UBE3A mutants expressed and puriﬁed from
bacteria. Reactions were stopped at the indicated times and the formation of self-ubiquitinated UBE3A was monitored by western blot using an anti-UBE3A
antibody. Representative images are shown from three independent experiments that produced similar results.

Structure–function analysis reveals a degenerate exosite in
UBE3A. The rich functional information provided by our screen
allowed us to perform extensive structure-function analyses of
UBE3A. When we mapped the spatial distribution of all loss and
gain-of-function mutations identiﬁed in our screen, we found
they localized to several structural features in the UBE3A HECT
domain (Fig. 4a). This included the C-lobe, which contains the
catalytic cysteine required for ubiquitin transfer25, a number of
mutations in the E2 binding region32, a group in a region of
unknown function, and one group that demarcated a recently
characterized non-covalent ubiquitin binding site in UBE3A

known as the exosite39. The exosite is best characterized in
NEDD4 subfamily HECT domain enzymes, where studies
showed that binding of monomeric or dimeric ubiquitin mediates
ubiquitin ligase activity36,40–43. Previous structural and mutational analyses determined that ubiquitin binding at the exosite
requires two principal contact points in NEDD442: a hydrophobic
patch formed by phenylalanine 707 (F707) in NEDD4 and isoleucine 44 (I44) in ubiquitin, and another hydrophobic contact
formed by two tyrosines (Y605 and Y634) that interact with
leucine 73 (L73) near the C-terminus of ubiquitin (Fig. 4b and
Supplementary Fig. 3a). Sequence alignment of the ubiquitin
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Fig. 4 UBE3A mutations demarcate a ubiquitin-binding exosite. a Crystal structure (PDB: 1C4Z) of the HECT domain of UBE3A (gray) bound to UBCH7
(gold). Mutations identiﬁed in our screen found in the catalytic C-lobe (purple), the E2 binding interface (blue), and two uncharacterized regions (pink and
green) are shown. All hyperactivating mutations are shown in red. b Crystal structure of the HECT domain of NEDD4 (gray) bound to a monomeric
ubiquitin molecule (pink) at its exosite (PDB: 4BBN). Note the binding of ubiquitin to NEDD4 occurs at a site homologous to a cluster of mutations (pink) in
UBE3A. c, d Surface (left) and ribbon (right) representations of the ubiquitin-binding interface for UBE3A (c) and NEDD4 (d). Ubiquitin is represented in
pink. Dotted boxes represent the position of hydrophobic binding pocket in NEDD4 that accepts L73 of the ubiquitin C-terminus. Surface charges are
indicated by color: positive (blue), negative (red), uncharged (white). e, f Rosetta simulations showing ensembles of low energy (high conﬁdence)
conformations for the C-terminus of ubiquitin docked to UBE3A. The divergent orientation of the ubiquitin tail caused by the Q588E mutation in UBE3A is
noted by the arrow. g, h Interface score versus RMSD plots showing Rosetta simulations under 880 Rosetta Energy Units (REU). The positions of the low
energy models are noted as stars according to the color scheme used in e, f. The gray dotted box demarcates WT-like tail conformations whereas the black
dotted box indicates the Q588E tail conformation.

contacting domain in UBE3A showed a high degree of conservation across species (Supplementary Fig. 3b). However,
whereas the NEDD4 F707 position is conserved in UBE3A (F665
in UBE3A), UBE3A lacks the aromatic residues at Y605 and Y634
(I564 and Q588, respectively) that are present in every
NEDD4 subfamily enzyme (Supplementary Fig. 3c).
Our observations raised the possibility that UBE3A possesses a
degenerate exosite that binds ubiquitin through mechanisms that
diverge from NEDD4 subfamily enzymes. To explore this
possibility, we used the crystal structure of the UBE3A HECT
domain and the co-crystal structure of ubiquitin bound to the
NEDD4 exosite (Fig. 4b; PDB: 4BBN) to perform constrained
rigid-body docking with the Rosetta molecular modeling
6

program44. Modeling showed that F665 in UBE3A contacts I44
of ubiquitin, and in functional experiments, we found that
mutation of F665 to alanine (F665A) caused a near-complete loss
of UBE3A activity in our BAR assay (Supplementary Fig. 3d),
demonstrating that F665 is indispensable for UBE3A activity. In
contrast, there were large structural changes at the second
ubiquitin binding site. Y605 and Y634 in NEDD4 contribute to
form a deep hydrophobic pocket that permits a stable interaction
with the side chain of L73 in ubiquitin (Fig. 4d). However, this
pocket is shallow in UBE3A and superimposing the orientation of
ubiquitin bound to NEDD4 resulted in steric clashing between
atoms in the sidechains of Q588 in UBE3A and L73 in ubiquitin
(Fig. 4c).
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Position Q588 is critical for ubiquitin binding at the UBE3A
exosite. Intriguingly, there were three mutations at the Q588
position tested in our screen including a substitution to glutamate
(Q588E), proline (Q588P), and arginine (Q588R), all of which
altered the overall charge in the ubiquitin-binding pocket of
UBE3A (Supplementary Fig. 3e). The Q588E mutation was a
gain-of-function mutation that elevated UBE3A activity
389% ± 35.8 above WT UBE3A levels (Fig. 3b and Supplementary
Data 1) whereas Q588P and Q588R abolished UBE3A ubiquitin
ligase activity (Supplementary Data 1). These functional observations suggested that Q588 is a critical residue that mediates
exosite function in UBE3A.
To further interrogate how Q588 impacts ubiquitin binding, we
used the Relax application in the Rosetta Macromolecular
modeling suite45, starting from the orientation of ubiquitin in
the NEDD4:ubiquitin co-crystal structure. High conﬁdence
models placed ubiquitin in a similar conformation relative to its
starting position, and key contacts typically made by ubiquitin
when bound to NEDD4 subfamily exosites were preserved in
UBE3A. Further analysis revealed an ensemble of closely-aligned
conformations in which the C-terminus of ubiquitin, including
L73, bound UBE3A through a series of interactions surrounding
the shallow hydrophobic pocket, including contacts with Q588
(Fig. 4e). Root mean square deviation (RMSD) versus Rosetta
score plots showed a broad funnel that corresponds to this
ensemble of similar C-terminal tail conformations (Fig. 4g). We
repeated this modeling with the Q588E variant and found that
RMSD versus Rosetta score plots revealed two divergent
populations of high-conﬁdence structures that corresponded to
distinct ubiquitin tail conformations docked to the Q588E exosite
(Fig. 4f, h). The ﬁrst population was similar to ubiquitin bound to
WT UBE3A (Fig. 4f). In contrast, the second set had an
alternative ubiquitin tail conformation in which the positive
charge from the adjacent arginine 72 (R72) residue in ubiquitin
contacted the negative charge resulting from the Q588E mutation
in UBE3A. Reanalysis of the WT modeling with this alternative
tail revealed there were four structures out of ~30,000 that had
this similar tail. Together, our analysis indicated that Q588E
mutation alters the mechanism by which ubiquitin binds
to UBE3A.
The Q588E mutation enhances ubiquitin binding to the exosite. Previous studies showed that ubiquitin binding to the exosite
of HECT domain enzymes facilitates its ubiquitin ligase
activity36,39,41–43,46. We performed a series of experiments to
explore if the charge at amino acid position 588 alters the afﬁnity
of ubiquitin binding to UBE3A. We began by performing comprehensive mutation analysis at position Q588 in UBE3A
(Fig. 5a). We tested a series of mutations at the Q588 site and
assessed UBE3A activity using the BAR assay (Fig. 5a and Supplementary Table 1). Consistent with a charge-dependent interaction between Q588E of UBE3A and R72 of ubiquitin, mutation
to a negatively-charged aspartate (Q588D) increased UBE3A
activity 320.25% ± 30 above WT UBE3A, whereas mutation to a
positively-charged lysine (Q588K, 6.60% ± 2.81) or histidine
(Q588H, 12.20% ± 1.62) resulted in an inactive enzyme. Hydrophobic or uncharged residues, including mutation to aromatic
residues present in NEDD4 sub-family enzymes (Q588Y and
Q588W), caused UBE3A to exhibit little activity (5.10% ± 0.97
and 11.99% ± 0.62, respectively), further suggesting the mechanism of ubiquitin binding to the UBE3A exosite is divergent from
NEDD4 sub-family enzymes. Finally, we found that polar residues such as serine (Q588S; 112.62% ± 11.27), threonine (Q588T;
125.72% ± 10.74), or asparagine (Q588N; 153.53% ± 11.91) all
produced an enzyme with comparable activity to WT UBE3A,

ARTICLE

suggesting that Q588 participates in hydrogen bonding with
ubiquitin in its native state.
We next tested whether the Q588E mutation enhances
ubiquitin binding to UBE3A. We ﬁrst accomplished this task
using ﬂuorescence polarimetry. Our experiments demonstrated
that ubiquitin bound the WT HECT domain with a dissociation
constant (KD) of 65.7 ± 28.5 μM (Fig. 5b), which was in line with
a previous report39, but bound with higher afﬁnity to the Q588E
HECT domain with a KD of 18.0 ± 1.5 μM (Fig. 5c). Second, we
utilized a new technique termed the mechanically transduced
immunosorbent (METRIS) assay47. In brief, this system measures
weak protein interactions by utilizing a protein that is covalently
conjugated to ferromagnetic particles placed on coverslips precoated with another protein of interest (Fig. 5d). A rotating
external magnetic ﬁeld is applied, which causes the beads to spin
in place. If there is an interaction between the two proteins of
interest, the bead migrates along the coverslip (Fig. 5e), and the
extent of this linear displacement is dependent on the strength of
the protein–protein interaction in the system. This displacement
is captured as the rolling parameter (ζ), and the value of the
rolling parameter scales in proportion with the afﬁnity of the
interaction (see “Methods” section for detailed information). We
performed this experiment by conjugating ubiquitin to ferromagnetic particles and calculating its rolling parameter on
UBE3A HECT domain-coated coverslips. We observed that WT
UBE3A yielded a rolling parameter of 0.178 ± 0.0056, whereas the
Q588E mutation increased the rolling parameter to
0.247 ± 0.0107, indicating enhanced afﬁnity between the two
proteins, and the Q588R mutation reduced the rolling parameter
to 0.114 ± 0.0021 (Fig. 5f). These results conﬁrmed our
ﬂuorescence polarimetry results that Q588E mutation enhances
ubiquitin binding.
Our ﬁndings provide the ﬁrst characterization of diseaserelevant mutations in the exosite of any HECT domain enzyme.
When we examined reported variants for other HECT domain
proteins, we found additional variants classiﬁed as VUS and likely
pathogenic/pathogenic in various disease contexts, including
several neurodevelopmental disorders (Supplementary Fig. 4).
Taken together, our experiments provide strong evidence that
ubiquitin binding to the UBE3A exosite is essential for proper
enzyme activity, and dysfunction at the exosite is a diseaserelevant mechanism that is shared across several human
disorders.
Excessive activity of maternal UBE3A is sufﬁcient to cause
neonatal behavioral impairments in mice. We next considered
the biological impact of UBE3A hyperactivating mutations and
their potential to contribute to pathology. We used CRISPR-Cas9
recombination to create a line of knock-in mice possessing a
Q588E mutation in UBE3A (Fig. 6a). All mutant animals were
born at expected Mendelian ratios and possessed indistinguishable body weights compared to WT littermates (Fig. 6b), indicating the absence of overt physical defects or delays in growth.
We began our characterization using heterozygous
Ube3amQ588E/pWT mice (mQ588E; Supplementary Fig. 5a), which
possess the Q588E mutation on the maternally-inherited allele,
and is thus expressed in neurons. Western blot analysis of the
cortex in mQ588E animals showed reduced mutant UBE3A
protein levels (Supplementary Fig. 5b). These observations were
consistent with enhanced self-targeted ubiquitination and
reduced steady-state levels observed previously for highly active
ubiquitin ligases36,37, including UBE3A12,48 (also see Supplementary Fig. 2a–c). We tested early life behaviors in our animals
using Fox’s battery of tests, which are designed to assess
sensorimotor development in juvenile mice49,50. We ﬁrst
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Fig. 5 The charge at Q588 dictates ubiquitin binding and UBE3A activity. a Heat plot showing normalized BAR values of mutations at position 588 in
UBE3A. White shading represents WT UBE3A activity levels, blue shading indicates loss-of-function, and red shading indicates gain-of-function. Scale bar
shows the percent change relative to WT UBE3A. N = 3 independent experiments for Q588S, Q588T, Q588N, Q588K, Q588P, Q588M, Q588G, Q588A,
Q588F, Q588Y, Q588W, Q588L, Q588V, Q588I, Q588C; n = 8 for Q588E, n = 6 for Q588D, n = 5 for Q588R, n = 4 for Q588H, *p < 0.05, **p < 0.005,
***p < 0.0005, One-sample t-test (two-tailed) with Benjamini–Hochberg multiple comparison correction (FDR = 0.05). b, c Fluorescence polarimetry to
obtain dissociation constants (KD) for ubiquitin binding to UBE3A. d, e Schematic (d) and representative images (e) from rolling magnetic probe assays
with beads conjugated to ubiquitin rolling on coverslips coated with WT, Q588E, and Q588R HECT domains from UBE3A. Dashed circle represents bead
position at t = 0 and arrowhead represents bead position t = 5 s after a magnetic ﬁeld was applied. Scale bar = 25 μm. f Plot showing mean ± SE of rolling
parameters (ζ) of different conditions. H2O and phosphate buffered saline (PBS) were used as negative controls and biotinylated beads rolling on
streptavidin-coated coverslips were used as a positive control. Note the ζ of Q588R is near negative control values. WT, n = 58; Q588E, n = 71; Q588R,
n = 42, ***p < 0.0001, One-way ANOVA with Tukey’s multiple comparisons test.

performed the surface righting reﬂex which measures the ability
of pups to right themselves when placed in a prone dorsal
position. In postnatal day 10 (P10) animals, we found that
mQ588E pups accomplished this task just as effectively as their
respective WT littermates (WT = 0.79 s ± 0.04, mQ588E = 0.88
s ± 0.09, Supplementary Fig. 5c). Moreover, we found no
differences between WT and mutant animals when testing
forepaw and hindpaw grasping reﬂexes (Supplementary Fig. 5d,
e). Next, we used the negative geotaxis assay which measures how
quickly an animal repositions itself vertically after being placed
facing down a 45° slope. Although we found no differences
between WT (56.59 s ± 6.46) and mQ588E (62.65 s ± 8.94)
animals in their ability to rotate (Supplementary Fig. 5f), we
observed that a much larger fraction of mQ588E mice
consistently fell from the testing apparatus as compared to WT
mice (Fig. 6c). This effect was speciﬁc to mQ588E mice as
Ube3amWT/pQ588E animals possessing a paternally-inherited
mutation (pQ588E; Supplementary Fig. 5a) were indistinguishable from WT littermates (Fig. 6d).
8

Our observations suggested that reﬂexive responses remained
largely intact, but raised the possibility that mQ588E animals
possessed deﬁcits in strength and motor coordination. This led us to
perform two additional tests in P10 mice. First, we performed the
front-limb suspension test and found that mQ588E on average
remained suspended on an elevated wire half as long as WT
littermates (WT = 7.73s ± 1.34, mQ588E = 3.82s ± 0.42) whereas no
effect was seen in pQ588E animals (WT = 4.90 ± 0.52, pQ588E =
4.13 ± 0.38; Fig. 6e, f). Next, we tested four-paw grip strength by
measuring the ability of pups to remain on a wire mesh rotated
slowly from a horizontal position (0°) to an inverted position (180°;
Fig. 6g). At P10, mQ588E animals performed poorly and fell from
the mesh at an average tilt angle of 129.48° ± 7.33 compared to
158.47° ± 3.34, for WT littermates (Fig. 6h). When we re-tested these
animals at P14, we found that mQ588E mice drastically improved in
their performance (171.56 ± 2.65) and were nearly indistinguishable
from WT littermates (177.33 ± 1.31; Fig. 6j), suggesting that motor
development was delayed in mQ588E mice. Meanwhile, pQ588E
mice showed no signiﬁcant differences from WT littermates at either
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Fig. 6 UBE3A Q588E mutation perturbs neurological function in a mouse model. a The genomic region containing the coding sequence for position Q588
in UBE3A was ampliﬁed and sequenced from WT and mQ588E mice. The arrow marks the mutated nucleotide. b Mean ± range of body weights of WT and
mutant mice at postnatal (P) day 5, 7, 10, and 14. Solid black: WT males (WT M), Open black: WT females (WT F), Solid gray: mQ588E males (mQ588E
M), Open gray: mQ588E females (mQ588E F), Solid blue: pQ588E males (pQ588E M), Open blue: pQ588E females (pQ588E F). The following numbers of
animals were used for each group: WT M: P5, n = 13; P7, n = 13; P9, n = 10; P14, n = 11. WT F: P5, n = 10; P7, n = 10; P9, n = 9; P14, n = 6. mQ588E M: P5,
n = 7; P7, n = 7; P9, n = 6; P14, n = 5. mQ588E F: P5, n = 9; P7, n = 9; P9, n = 8; P14, n = 5. pQ588E M: P5, n = 12; P7, n = 9; P9, n = 11; P14, n = 8. pQ588E
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negative geotaxis apparatus over three trials are shown. Values reﬂect the average of three trials per animal. WT, n = 29 animals; mQ588E, n = 16 animals
in c; WT, n = 21 animals; pQ588E, n = 26 animals in d. e, f Individual times and the mean ± SE for mQ588E (e, gray) and pQ588E (f, blue) mice in the front
limb suspension test are shown. Each animal was tested three times and the average of the three trials was used in for analysis. WT, n = 29 animals;
mQ588E, n = 16 animals in e; WT, n = 21 animals; mQ588E, n = 26 animals in f, **p = 0.001, Mann–Whitney U-test, exact signiﬁcance (two-tailed).
g–k Schematic (g) and individual and mean ± SE values for the four-paw grip strength test at mQ588E (h, l gray) and pQ588E (j, k blue) animals. Animals
were tested at P10 (h, j) and at P14 (I, k) as indicated. **p = 0.001 (h), *p = 0.026 (j), Mann–Whitney U-test, exact signiﬁcance (two-tailed). WT, n = 29
animals; mQ588E, n = 16 animals (h, j); WT, n = 21 animals; pQ588E, n = 26 animals (i); WT, n = 17 animals and pQ588E, n = 22 animals (k). l,
m Mean ± SE values showing the number of calls at P5, P7, and P9 for WT (black) and mQ588E (gray) littermates (l), and in WT (black) and pQ588E
(blue) littermates (m); **p = 0.001 at P5, *p = 0.038 at P9, Repeated measures ANOVA. WT: P5–P7, n = 31 animals; mQ588E: P5–P9, n = 23 animals (l);
WT: P5 and P7, n = 21 animals, P9, n = 15 animals; pQ588E: P5, n = 32 animals, P7, n = 27 animals, P9, n = 26 animals (m).
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timepoint (P10: WT = 157.70 ± 4.26, pQ588E = 148.81 ± 4.64; P14:
WT = 180.0 ± 0, pQ588E = 178.64 ± 1.36; Fig. 6i, k).
Finally, we measured ultrasonic vocalizations (USVs) to
determine whether early-life communication is affected in
mQ588E animals. We found that on average, the number of USVs
produced by WT animals increased gradually from 68.11 ± 12.67
calls at P5, to 80.81 ± 15.53 at P7, and 95.03 ± 19.10 at P9. In
contrast, mQ588E animals produced dramatically fewer calls at P5
(12.57 ± 3.32) and at P9 (42.04 ± 11.55; Fig. 6l). Intriguingly, these
results were opposite to neonatal Angelman syndrome model mice,
which were shown to produce increased vocalizations51. We also
observed higher pitched vocalizations, shorter call durations, and
longer pause durations (Supplementary Fig. 5g–i) to varying
degrees in mQ588E animals. In contrast, there were no differences
in the number of vocalizations at any timepoint between pQ588E
mice and their WT littermates (Fig. 6m), and a very subtle
difference in pitch frequency at P5 (Supplementary Fig. 5j) with no
differences in call duration or pause duration (Supplementary
Fig. 5k, l). Taken together, our observations provide direct evidence
that hyperactivation of maternal, but not paternal UBE3A, is
sufﬁcient to delay motor development and produce deﬁcits in early
life communication.
Hyperactivating mutations in UBE3A may contribute to neurodevelopmental phenotypes that are distinct from Angelman
syndrome. Although AS is clinically recognizable52, phenotypes
caused by excessive UBE3A activity are not well documented.
Thus, when we compared our functional screening results with
variant classiﬁcations in the ClinVar database, we predicted that a
greater number of loss-of-function variants would be classiﬁed as
pathogenic whereas gain-of-function mutations would be classiﬁed as VUS. Consistent with our hypothesis, our data showed
that about half (50.6%) of loss-of-function mutations identiﬁed in
our screen were deemed pathogenic whereas most gain-offunction mutations were classiﬁed as VUS (84%) with a few
designated as benign (16%) and none designated as pathogenic
(Fig. 7a).
To gain further clarity into human phenotypes, we collaborated
with clinical centers to collect data from 17 individuals possessing
hyperactivating mutations identiﬁed in our study. A summary of
their clinical phenotypes is presented in Supplementary Table 2
and a detailed account for each individual is presented in
our Supplementary Information (Supplementary Note 1). Our
data indicated that hyperactivating mutations are typically
maternally inherited, and individuals generally exhibit intellectual
disability, seizures, and autism. In some cases, phenotypes distinct
from either classic AS or Dup15q were reported. However, none
of the individuals examined in our study were diagnosed with AS.
Here we highlight two families in which mutations segregated
with affected individuals. Individual 1 was an adult who possessed
a T787A mutation that raised UBE3A activity 517.81% ± 49.3
above WT levels. The individual was diagnosed with failure to
thrive, hypotonia, feeding difﬁculties, and global developmental
delay as a child. Autistic behaviors, intellectual disability, and
epilepsy were also observed. In addition, Individual 1 was noted
to possess small hands and feet, which are typical characteristics
seen in Prader–Willi syndrome patients, but no methylation
abnormalities in chromosome 15 were detected. The observed
phenotypes were not consistent with AS. Individual 1 also had
two siblings: one who was typically developing and did not
possess the T787A mutation. The other sibling inherited the
T787A mutation (noted here as Individual 2) and displayed
autistic behaviors and was non-verbal until the age of 4 (Fig. 7b).
It was not known at the time of this report if Individual 2
exhibited seizures. Sequencing analysis conﬁrmed the T787A
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Fig. 7 UBE3A hyperactivity causes neurodevelopmental dysfunction.
a Clinical interpretations in ClinVar for variants characterized in this study.
The number of individual reports contained in ClinVar are shown for
pathogenic/likely pathogenic (black), uncertain/conﬂicting (gray), and
benign/likely benign (white) variants. b, c Pedigree chart for the T787A (b)
and L726Δ (c) hyperactive mutations. ID intellectual disability, DD
developmental delay, ASD autism spectrum disorder, ADHD attentiondeﬁcit/hyperactivity disorder.

mutation was maternally inherited, however, we were not able to
establish the parent-of-origin or the mutation in the mother.
Individual 5 was an adolescent who possessed an in-frame
deletion that resulted in the removal of leucine 726 (L726Δ) and
raised UBE3A activity 180.75% ± 9.9 above WT levels. The
individual presented with global developmental delay, microcephaly, and intractable epilepsy requiring vagal nerve stimulation placement. Delayed motor and language milestones were
evident in early childhood and the proband was later diagnosed
with quadriplegic cerebral palsy and severe intellectual disability.
Individual 5 is currently G-tube dependent for feeding, possesses
generalized muscle atrophy and spasticity in the lower extremities, pectus carinatum deformity, severe thoracolumbar scoliosis
and thoracic kyphosis. Osteoporosis in the femoral head and neck
was also evident. Individual 5 was found to be heterozygous for a
pathogenic ADAR1 variant that was inherited from the mother.
However, as ADAR1 mutation causes an autosomal recessive
disorder, this variant was not determined to be causative of
disease phenotypes53,54. Individual 5 had three siblings. One
adolescent sibling (Individual 6), possessed the same L726Δ
variant and exhibited intellectual disability and ADHD. The
cognitive ability of Individual 6 was estimated at 4 years of
developmental age and required special resources at school
(Fig. 7c). Individual 6 was not able to read or count and had
limited speech. The proband did not exhibit seizures and clinical
and behavioral phenotypes, as well as facial features, were not
consistent with a diagnosis of AS. A second adolescent sibling did
not possess the L726Δ mutation and was typically developing.
The ﬁnal sibling was an adolescent maternal half-sibling who
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inherited the L726Δ mutation (noted here as Individual 7).
Individual 7 was diagnosed with ADHD and was noted for
possessing learning difﬁculties. The proband required an
individualized education program (IEP) at school, including
special classes for math and social studies. No other abnormalities
were noted. Sequencing analysis conﬁrmed the L726Δ mutation
was maternally inherited, but the parent-of-origin was unknown
for the mother.
Discussion
Historically, the need to infer the impact of mutations strictly
from sequence changes has biased the discovery of diseasecausing genes toward lesions that produce loss-of-function alleles.
Our functional analyses of missense variants in UBE3A revealed
that ~12% of variants cause a gain of enzyme function. We found
that hyperactivating mutations segregate with affected phenotypes in two unrelated families, and consistent with the neuronal
imprinting of UBE3A, our mouse modeling and patient data both
strongly suggest that hyperactivating mutations confer an
increased risk for pathogenicity when present on the maternallyinherited allele.
Our functional variant analysis allowed us to identify a group
of mutations in the UBE3A exosite39, thereby implicating its
dysfunction in UBE3A-dependent disorders. In general, the
exosite is thought to facilitate ubiquitin chain elongation by
binding the distal ubiquitin on a growing chain and stabilizing
ubiquitinated target proteins to the E3 enzyme41–43,46. However,
this mechanism appears context-dependent as ubiquitin binding
to the exosite can also inhibit chain elongation40 and ubiquitin
variants that bind the exosite with high afﬁnity can alter enzyme
activity in complex ways36. We also found that additional HECT
domain enzymes possess VUS or pathogenic/likely pathogenic
variants within their exosites (Supplementary Fig. 4). Examples
include NEDD4-2, which is implicated in periventricular nodular
heterotopia37, HECW2, which is implicated in a neurodevelopmental disorder with hypotonia, seizures, and absent
language55,56, and HUWE1, which contains a mutation (Y4106C)
at a position that is analogous to Q588 in UBE3A and is associated with an X-linked form of intellectual disability57 (Supplementary Fig. 4c). Although the functional impact of these variants
awaits further study, our observations suggest that exosite dysfunction is a common mechanism that underlies additional
neurodevelopmental disorders.
We found that UBE3A hyperactivity causes a general reduction
in steady-state enzyme levels due to enhanced self-targeted
degradation both in vitro and in vivo (Supplementary Figs. 2 and
5b), a result that is contrary to UBE3A duplication, which leads to
increased amounts of protein58. These observations paint a
complex picture about the pathogenic mechanisms of gain-offunction UBE3A variants, and our study does not rule out the
possibility that such variants may actually cause a loss-of-function
state in vivo by lowering overall UBE3A levels in the cell. However, we note that enhanced self-targeting is an enigmatic process
that can reﬂect both enzyme loss and gain-of-function states for
UBE3A as well as for other ubiquitin ligase enzymes. Previous
studies with various HECT domain enzymes have shown that
gain-of-function mutations cause a reduction in steady-state
enzyme levels through enhanced self-targeted degradation12,37,59,
and AS-linked missense mutations in UBE3A known to cause
constitutive self-targeted degradation12 (T106P, T106K, and
I130T), produced a loss-of-function response in our BAR assay
(Fig. 1d and Supplementary Data 1). In addition, UBE3A is
known to undergo self-targeted degradation after the depletion of
its substrates60, suggesting that heightened self-targeted degradation may be a predicted outcome in the context of enzyme
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gain-of-function. Additional studies will be required to distinguish these intriguing possibilities and will provide greater insight
into the mechanisms of UBE3A gain-of-function variants in
disease.
Our work strongly suggests that gain-of-function mutations in
UBE3A confer an increased risk for neurodevelopmental
pathology, however, there were variables in our clinical data that
limited our ability to elucidate the extent to which excessive
UBE3A activity contributes to disease phenotypes. First, our
mouse modeling experiments indicated that gain-of-function of
maternal UBE3A is required to alter behavioral phenotypes
(Fig. 6 and Supplementary Fig. 5). We were able to establish
maternal inheritance for some individuals, however, we were
unable to determine the parent-of-origin for Individuals 3, 4, 10,
13–17 (Supplementary Table 2). Second, our study could not
resolve the contribution of additional genetic and environmental
inﬂuences on patient phenotypes. For example, Individuals 8 and
10 both possessed variants in STXBP1, a gene linked to pediatric
seizures and intellectual disability61, and Individual 10 was
diagnosed with fetal alcohol syndrome (Supplementary Table 2).
Moreover, several patients in our cohort possessed skeletal malformations not typically associated with UBE3A dysfunction,
reﬂecting the presence of additional contributing factors for disease. This was particularly notable for Individuals 5–6, who were
siblings who possessed the same L726Δ variant. Individual 5 was
more severely affected and presented with quadriplegic cerebral
palsy, pectus carinatum deformity, severe thoracolumbar scoliosis, and thoracic kyphosis, which were all phenotypes that were
absent in the siblings.
Seizures were a prevalent phenotype observed in our patient
cohort, and this observation was consistent with the high degree
of penetrance of epilepsy in UBE3A-dependent disorders8–11.
However, we stress that careful consideration must be given when
attributing this phenotype to gain-of-function mutations in
UBE3A. A previous study noted that individuals who possess a
microduplication encompassing only maternal UBE3A exhibited
developmental delay, intellectual disability, and behavioral
abnormalities, but none of these individuals presented with
seizures14. In the current study, we observed that seizures were
not always a shared phenotype among siblings with the same
UBE3A gain-of-function mutation (Fig. 7b). For example, seizures were a prominent phenotype in Individual 5, but they were
absent in the siblings who possessed the same maternal L726Δ
mutation (Individuals 6 and 7). Although we cannot determine at
this time whether excessive UBE3A activity is a contributing
factor for seizure susceptibility, our study suggests that UBE3A
gain-of-function alone is likely insufﬁcient to produce this
phenotype.
Finally, our results have broad implications for the nosology of
developmental disorders. The results of our study add to the
emerging literature suggesting that functional valence can provide
a method to distinguish mechanistic subtypes of monogenic
disorders. For example, a recent series of studies found that gainof-function mutations in the sodium channel gene SCN2A result
in infantile seizures whereas loss-of-function mutations produce
autistic phenotypes without seizures62–64. Although additional
large-scale functional studies of missense variants remain scarce,
there are many examples of copy number variations in wellestablished disease genes that produce distinct disease phenotypes. These include the Rett syndrome gene MeCP265, the Fragile
X syndrome gene FMR166, and NSD1, whose deletion67 causes
Sotos syndrome and duplication68 results in a poorly characterized growth disorder. With the increasing development of genetic
therapies, understanding such mechanistic differences will be
critical for the design and safe implementation of these
approaches.
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Methods
Molecular biology and antibodies. The nomenclature used in this study was
based on the amino acid sequence from human UBE3A isoform I (NCBI accession:
NP_001361390.1). Myc epitope tags were placed on the N-terminus of UBE3A by
polymerase chain reaction and all UBE3A constructs were cloned into pCIG2
plasmid DNA69, using SacI and XmaI sites. This vector is driven by a chicken βactin promoter with bi-cistronic GFP expression through an internal ribosome
entry site (IRES), which allowed us to control for transfection efﬁciency and
loading in our in vitro assays. All constructs were veriﬁed by sequencing. Diseaselinked UBE3A missense mutations used in this study were identiﬁed in previous
publications12,21–30, and are listed in the ClinVar1 and gnomAD databases2.
Cloning for C21Y, R39H, T106P, T106K, C117R, I130T, A178T, N243K, E269G,
L273F, I329T, S349P, R477P, M478I, R482P, T485A, L502P, R506C, E550K, and
E550L variants were described previously12. For most constructs, variants were
introduced by PCR using site-speciﬁc primers (Integrated DNA Technologies). A
complete list of oligonucleotide sequences used in this study are presented in
Supplementary Table 3. The STOPΔ variant causes an extension of the C-terminus
of UBE3A70. Primers matching this extended sequence were designed, annealed,
and ligated using an internal SphI site and XmaI. To generate FLAG-tagged
RING1B, we placed the epitope tag on the N-terminus of RING1B by polymerase
chain reaction using a plasmid encoding a catalytically inactive human RING1B
(RING1B I53S)71 and cloned into pCIG2 using SacI and XmaI sites. The vector to
express the pGEX GST-TEV-Cys-ubiquitin used in the METRIS assay was acquired
as a gift from Dr. Brenda Schulman (Max Planck) and described in a previous
study72. pGL3-BAR and TK-Renilla constructs were described previously12. The
pCDNA3.1 3× FLAG-tagged ubiquitin was a gift from Dr. Mark Zylka (University
of North Carolina) and used in a previous study12. For UBE3A protein puriﬁcation,
an N-terminal 6×-His tag was added to each UBE3A missense variant by polymerase chain reaction and cloned into the pET-45b(+) plasmid (EMD Millipore)
using SacI and NotI restriction sites. Primary antibodies used were mouse anti-Myc
(1:1000, Millipore Sigma, #05-419), mouse anti-UBE3A (1:1000, BD Biosciences,
#611416), mouse anti-GFP (Santa Cruz Biotechnology #sc-9996), and mouse antiFLAG (1:1000, #F3165). All secondary antibodies were obtained from LI-COR
Biosciences: donkey anti-rabbit 800CW (926-32213), donkey anti-rabbit 680RD
(925-68073), donkey anti-mouse 800CW (926-32212), and donkey anti-mouse
680RD (926-68072); all used at a dilution of 1:10,000.
Cell culture and transfection. HEK293T cells (ATCC) were maintained in a 5%
CO2 humidiﬁed incubator in DMEM containing 25 mM glucose, 0.4 mM glutamine, and 1 mM Sodium Pyruvate (Gibco #10569044), supplemented with 10%
fetal bovine serum (Gibco, #16140071) and 1× antibiotic–antimycotic containing
penicillin, streptomycin, and amphotericin B (ThermoFisher #15240062). For
biochemical analyses, transfections were performed using FuGENE (Promega)
according to the manufacturer’s instructions. HEK293T cells were lysed in 2×
sample buffer (Fisher NuPAGE™ LDS Sample Buffer #NP0008) supplemented with
5 mM DTT and 1× EDTA-free Pierce protease inhibitor mini tablets (ThermoFisher #A32955). Lysates were boiled and proteins were resolved by 4–20% SDSPAGE and transferred to nitrocellulose membranes (Bio-Rad). Membranes were
blocked in 1× ﬁsh gelatin blocking agent (Biotium #22010) and probed with the
appropriate primary antibodies overnight at 4 °C or 2 h at RT. Protein bands were
visualized using the Odyssey CLx infrared imaging system and Image Studio
v5.2 software (LI-Cor Biosciences) and western blots analyzed using ImageJ v2.1.0/
1.53c.
Luciferase assays. BAR assays were performed in 96-well plates for all experiments. HEK293T cells were plated at a density of 10,000/well. Cells were transiently
transfected with 10 ng of pRL-TK-Renilla, 30 ng of BAR-pGL3, and 30 ng of the
indicated constructs using the FuGENE (Promega) transfection reagent, according
to the manufacturer’s instructions. Forty-eight hours after transfection, reporter
gene expression was assessed using the Dual-Luciferase reporter assay system
(Promega) and measured on a Synergy HTX Multi-Mode Reader (BioTek) using
Gen5 software v3.08. Luciferase activity was normalized against Renilla activity,
and UBE3A missense variant signals were normalized to WT UBE3A.
Protein expression and puriﬁcation. For protein expression, pET-45b(+) UBE3A
constructs were transformed into chloramphenicol-resistant Rosetta™ BL21DE3
competent E. coli cells (Sigma-Aldrich #70954). The next day, a colony was picked
and transferred into 1 mL of growth media (10 g/L tryptone, 15 g/L yeast extract,
5 g/L NaCl, and 5 g/L K2HPO4. Just before inoculation, the following was added:
1 mM MgSO4, 10 mL/L trace metals (pre-mixed in deionized water and stored at
RT: 0.3 g/L CoSO4 * 7 H2O, 1.5 g/L MnCl2 * 4 H2O, 0.22 g/L CuSO4 * 5 H2O,
0.3 g/L H3BO3, 0.25 g/L Na2MoO4 * 2 H2O, 0.5 g/L ZnCl2, 0.93 g/L Na2EDTA * 2
H2O, and 6.17 g/L FeCl3), 0.5% glycerol, 100 µg/mL ampicillin, and 30 µg/mL
chloramphenicol). Cultures were allowed to shake at 225 RPM at 37 °C for 2–5 h.
Afterwards, 1 mL of culture was transferred into 50 mL of growth media and
incubated overnight at 225 RPM at 25 °C. The next morning, 500 mL of induction
media (inoculation media + 0.5% glucose) was inoculated to an OD600 of 0.4. The
induction culture was shaken at 175 RPM at 37 °C until an O.D. of 0.7 was reached
(~2 h). Five hundred microliters of 1 M IPTG was then added to induce UBE3A
12

protein expression and the culture was allowed to shake at 175 RPM at 25 °C for
6 h. Cells were pelleted by centrifugation at 1425×g at 4 °C for 15 min. For protein
puriﬁcation, pellets were resuspended in 25 mL lysis buffer (25 mM HEPES pH 7.4,
150 mM NaCl, 10% glycerol, 1× EDTA-free Pierce™ protease inhibitor mini tablets
(ThermoFisher #A32955), 10 mM imidazole and lysed by sonication. After centrifugation at 15,000×g for 15 min at 4 °C, the resulting lysate was incubated with
HisPur™ Ni-NTA Resin beads (ThermoFisher #88221) at 4 °C for 60 min. The
beads were collected on elution columns and washed with wash buffer (25 mM
HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 20 mM imidazole). UBE3A was eluted
with 500 mM imidazole. UBE3A was further puriﬁed through size-exclusion
chromatography and buffer exchange with 7 K MWCO Zeba™ Spin desalting
columns (Thermo Scientiﬁc #89889) according to the manufacturer’s instructions
(ﬁnal buffer: 25 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol).

Ubiquitination assays. In vitro ubiquitination assays were performed using
human His6 Ubiquitin-activating enzyme/UBE1 recombinant protein (R&D Systems, #E304050), 10× E3 ligase reaction buffer (R&D Systems, #B-71), UbcH7
recombinant protein (R&D Systems, #E2640100), human FLAG-ubiquitin
recombinant protein (R&D Systems, #U12002M), and ATP. (Sigma). Assays were
performed as described previously12. In brief, a single reaction contained 1x E3
ligase reaction buffer, 0.1 µM UBE1, 0.5 µM UBE2L3 (UbcH7), 12.5 µM FLAGubiquitin, 2 µM ATP, and 4 µg of puriﬁed UBE3A. The reaction was allowed to
proceed at room temperature for the indicated times. Reactions were stopped by
adding 2× Laemmli buffer and boiling for 5 min. UBE3A ubiquitination was also
assayed in HEK293T cells treated with 30 μM MG-132 for 1 h. The cells were then
lysed in RIPA buffer containing 1% SDS and 30 μM MG-132. Cell lysates were
boiled for 20 min and clariﬁed by centrifugation at 15,000×g for 10 min. The
resulting supernatant was diluted 1:10 (v/v) in an immunoprecipitation buffer
(20 mM HEPES pH 7.4, 50 mM KCl, 1% Triton X-100). For UBE3A immunoprecipitation, an anti-Myc-conjugated afﬁnity gel (Sigma #A7470) was used at 4 °C
for 1 h. The ﬁnal complex was washed three times with wash buffer (immunoprecipitation buffer containing 125 mM NaCl), resuspended in sample buffer, and
subject to SDS-PAGE and immunoblot analysis.

Protein modeling with Rosetta. To model ubiquitin bound to the exosite of
UBE3A, we used the Rosetta Relax application through the Rosetta scripts
interface45,73. To build a starting structure we aligned UBE3A (PDB ID: 1C4Z)25 to
NEDD4 in the NEDD4-ubiquitin co-complex (PDB ID: 4BBN)42, which has a
complete ubiquitin tail. We used this starting structure with the relax application in
Rosetta to generate 30,000 models of ubiquitin docked to UBE3A. To calculate the
RMSD of the ubiquitin tail, we used ProFit with residues 71–76 of ubiquitin. The
same protocol was used with WT UBE3A, and the Q588E and Q588R mutations
which were generated using the Rosetta ﬁxbb application74.
Sequence alignments of UBE3A from various species were performed using
amino acid sequences with the following accession numbers: mouse
(NP_001029134.1), frog (NP_001080693.1), ﬁsh (NP_001007319.1), and ﬂy
(NP_648452.1). Sequence alignments of UBE3A with human NEDD4 subfamily
enzymes were performed using amino acid sequences from the following accession
numbers: NEDD4 (NP_006145.2), NEDD4-2 (NP_001138439.1), HUWE1
(NP_113584.3), HECW1 (NP_055867.3), HECW2 (NP_001335697.1), SMURF1
(NP_001186776.1), SMURF2 (NP_073576.1), WWP1 (NP_008944.1), WWP2
(NP_001257383.1), and ITCH (NP_001311127.1). PDB IDs for additional crystal
structures of HECT domains used in this study are as follows: NEDD4-2 (3JVZ),
HUWE1 (3H1D), WWP1 (6J1Y), and ITCH (3TUG).

METRIS assay to measure UBE3A-Ubiquitin interaction. We used a method
amenable for measuring weak and transient protein interactions with minimal
protein quantities using rolling magnetic probes (RMP). This experiment measures
the translational displacement of magnetic particles, immobilized with ubiquitin,
on a surface that contains immobilized UBE3A. Streptavidin-biotin was used to
immobilize proteins to their respective material. To attach ubiquitin to the magnetic beads we used a commonly used ubiquitin variant with an N-terminal
cysteine. Cysteine biotinylation was carried out using Poly(ethylene glycol) [N-(2maleimidoethyl)carbamoyl]methyl ether 2-(biotinylamino)ethane (Sigma #757748)
(Biotin-maleamide). Ubiquitin was singly biotinylated and puriﬁed over size
exclusion chromatography, and dialyzed to remove excess biotin-maleamide.
The streptavidin coated ferromagnetic particles, provided by Spherotech were
composed of a core of polystyrene and CrO2. Ten liters of the bead slurry (1.0% w/
v) was used to coat with biotinylated-ubiquitin at room temperature for at least 2 h.
The amount of protein used was 50× the theoretical limit needed to coat each bead
to that ensure all of the binding sites on the beads were occupied (1 mg of beads
bound 0.16 nmoles of biotin). Biotinylated UBE3A was ﬁxed to avidin-coated glass
slides (Arrayit) with a ligand density of 1.1 × 1010 ligands per mm2. Microﬂuidic
channels were created on this substrate using two pieces of double-sided tape
(3 M). The amount of proteins inserted was enough to coat the channel surface 50×
the theoretical limit to ensure that all of the sites on the substrate were coated. The
substrate and solution were left in a sealed container for 2 h, then washed to
remove excess unbound protein.
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Coated ferromagnetic beads were diluted approximately 2000-fold, to reduce
the probability of bead aggregation. Beads were placed into channels on the coated
slides and sealed. The sealed slide containing the magnetic particles and
functionalized substrate was placed in a Helmholtz-inspired apparatus. A clockwise
ﬁeld was actuated at 1 Hz for 5 s, turned off for 5 s, then a counter-clockwise ﬁeld
was actuated at 1 Hz for 5 s, then turned off for 5 s. This actuation cycle was
repeated 18 times. Video captured from the CMOS camera was converted into
an.avi ﬁle using ArcSoft Media Converter 8 then converted into a sequence of jpeg
images. Able Particle Tracker was used to track the motion of the beads and the
data then imported into Mathematica for analysis.
To analyze the rolling of the particles, we used a dimensionless value called the
rolling parameter (ζ) which is a ratio between the maximum possible rolling (i.e.,
all of the rotational torque is converted to translational displacement) and the
observed rolling of the particles. The rolling parameter is given by the following
equation:
ζ ¼ Δx=πDτω;
where x is translational displacement, D is the diameter of the beads, τ is the
actuation time, and ω is the frequency of the rotation of the magnetic ﬁeld.
Fluorescence polarimetry. The HECT domain from WT UBE3A was cloned into
pRSFDuet-1 (Novagen) with an Octa-histidine-GST double afﬁnity tag fused to the
N-terminus. A TEV protease cleavage sequence was introduced between His-GST
and the HECT domain to excise the afﬁnity tag. The UBE3A Q588E mutant was
made by site-directed mutagenesis. Both wild type and UBE3A Q588E were
transformed into E. coli BL21 codon plus RIL (Agilent) cells, and expression was
induced by adding 0.6 mM IPTG at 16 °C for 18 h. UBE3A was puriﬁed on a nickel
afﬁnity gravity column followed by TEV protease digestion and size exclusion
puriﬁcation on an AKTA FPLC (GE healthcare). The purity of the fractions was
conﬁrmed by SDS-gel electrophoresis, combined, and concentrated to ~10 mg/mL
for biophysical assays. N-terminal ﬂuorescein-labeled ubiquitin (Anaspec) was
prepared as described previously36. Mixtures of 1 µM ﬂuorescein-labeled ubiquitin
and varied concentrations of UBE3A were prepared in a 384-well plate. Milliﬂuorescence polarization (mP) values were detected by a Tecan Inﬁnite M1000Pro
plate reader at 30 °C. Iterative nonlinear curve ﬁtting using a one-site speciﬁc
binding model was applied in ProFit to obtain binding afﬁnities (KD).
Generation of UBE3A Q588E mice. All animal procedures were performed in
accordance with guidelines set by the Washington University Institutional Animal
Care and Use Committee. Mice were maintained in standard housing conditions,
where food and water were provided ad libitum. Each generation was crossed to
wildtype C57BL/J6 mice from Jackson labs.
An analogous Q585E mutation in mouse UBE3A (Q585E, NP_001029134.1)
was created by designing single guide RNAs (sgRNAs) to create a C<G substitution
at Chr7:59,286,122 (GRCm38/mm10 assembly). The resulting mutation altered a
CAG codon into GAG (Fig. S4A). The gRNAs were cloned into the pX330 Cas9
expression plasmid (Addgene), transfected into N2a cells, and validated using the
T7 enzyme assay. Validation was performed in the Transgenic Vectors Core at the
Washington University School of Medicine. The gRNAs were in vitro transcribed
using MEGAShortScript (Ambion) and Cas9 mRNA was in vitro transcribed, G
capped and poly-A tailed using the mMessageMachine kit (Ambion). mRNA of
Cas9 and the selected gRNA were injected into hybrid C57Bl/6J/JxCBA fertilized
eggs at the mouse genetics core at the Washington University School of Medicine.
This resulted in 145 founders which were all deep sequenced at the expected cut
sites to identify which alleles were present. We identiﬁed six founders in which offtarget recombination events were not observed, and the Q588E allele represented
>90% of the sequenced reads. We selected two founders from this pool and
perform additional deep sequencing analysis four kilobases surrounding the
targeted region to rule out the presence of additional off-target recombination
events.
Founders were crossed to WT C57/Bl6 mice (Jackson Laboratory #000664).
Animals were backcrossed for at least six generations prior to use in the study. Mice
were genotyped using either tail-tips or toe clippings. Tissue samples were incubated
overnight at 55 °C in 400 µL tail lysis buffer (0.1 M Tris pH8.8, 0.2 M NaCl, 0.005 M
EDTA, 0.5% SDS + 8 µL proteinase K (Thermo Scientiﬁc #BP1700500). Proteinase K
was inactivated by incubation at 95 °C for 10 min and genomic DNA puriﬁed by
isopropanol precipitation. PCR was performed by amplifying a 407 bp fragment with
~200 bp ﬂanking either side of the Q588 codon. The products were puriﬁed using a
PCR puriﬁcation kit (Qiagen) and submitted for Sanger sequencing (Genewiz). PCR
was performed using GoTaq DNA polymerase (Promega #M3001). An initial
denaturation step of 95 °C for 2 min was used followed by 35 cycles of 95 °C for 15 s,
43 °C for 15 s, and an extension step of 72 °C for 30 s.
Animal behavior. Mice were group housed in standard mouse cages with ad
libitum access to food and water, and with a 12 h light/dark cycle in a temperature
(~20–22 °C) and humidity-controlled (50% relative humidity) barrier facility. To
generate mQ588E animals, heterozygous females possessing the Q588E mutation
on the paternal copy of UBE3A were crossed with WT C57BL/6 males, and to
generate pQ588E animals, heterozygous males possessing the Q588E mutation on

ARTICLE

the paternal copy were crossed with WT females. For all mQ588E tests used in this
paper, a cohort of 45 mice in total was used: 20 female (11 WT, 9 mQ588E) and 25
male (18 WT, 7 mQ588E), and for all pQ588E tests, a cohort of 53 mice was used:
31 female (13 WT and 18 pQ588E) and 21 male (8 WT and 13 pQ588E). Although
sex differences were assessed in all experiments, no signiﬁcant differences observed
and data from male and female mice was pooled for our analyses. All behavioral
experiments were performed blind to genotype by a female experimenter and also
analyzed blind to genotype.
Neonatal motor assessments were performed as described in refs. 49,50. Pups
were habituated for at least 10 min in the testing room. At P10, grip strength,
forelimb suspension, and negative geotaxis was assessed. On P14, grip strength, the
surface righting reﬂex, and the grasping reﬂex were measured. Each task was
performed by each mouse in triplicate and mice were allowed at least 1 min to rest
between trials. The values of the three trials were averaged for analysis.
Negative geotaxis was determined by placing the pup head downward on a ﬂat,
padded 45° incline and holding it for ﬁve seconds to allow it to acclimate. The pup was
released, and the time it took the pup to turn to face upward was measured (2 min
max). Surface righting reﬂex was conducted by placing the pup on its back on a ﬂat,
padded surface for 5 s and recording the time until the pup positioned itself upright and
touched all four paws on the surface. Grasping reﬂex was determined by holding the
mouse vertically by the scruff of the neck, and gently stroking each paw, palm-toﬁngertip, ﬁve times with the blunt, rounded side of a razor blade. A successful trial was
recorded if the pup grasped the blade within ﬁve strokes. Forelimb suspension was
measured by positioning pups in front of a stable wire strung horizontally across the
opening of a wire cup with a padded bottom. Once the mouse grasped the wire with
both forepaws, the mouse was released, and the time until the mouse dropped to the
padded bottom of the cup was recorded. Grip strength was measured by placing the
pup on a plastic mesh screen laid upon a ﬂat, padded surface. Keeping one edge of the
screen ﬂat against the table, the screen was slowly rotated (~12 s total) until the screen
was inverted (180°). A protractor was placed perpendicularly to the screen to measure
the angle at which the pup fell from the screen.
USV recordings were performed as described in ref. 75 to assess early
communicative behaviors. Pup vocalizations were recorded on postnatal days 5, 7,
and 9 in the home colony room of the pups. For each recording session, the dam
was placed in a separate cage, and the home cage containing the pups was placed in
a warming box (Harvard Apparatus) set to 33 °C to ensure pup temperature in the
nest remained between 34–37 °C. An individual pup was selected and its skin
temperature taken from the lower dorsal region using a non-contact HDE Infrared
Thermometer, as it is known that decreased body temperature results in increased
number of USVs76. We did not observe a difference in body temperature between
genotypes. The pup was then placed in an empty standard mouse cage which in
turn was placed within an MDF sound-attenuating box (Med Associates)
(36 × 64 × 60 cm). The doors of the sound-attenuating box were shut and USVs
were detected using an Avisoft UltraSoundGate CM16 microphone positioned
5 cm above the bottom of the cage, along with the Avisoft UltraSoundGate 116H
ampliﬁer and the Avisoft v4.3.01 recorder software. Gain was set to 3 dB and the
sampling rate set to 250 kHz. Pups were recorded for 3 min, after which their
weight was taken and they were returned to their home cage within the warming
box. MATLAB software was used to prepare sonograms of the recordings
(frequency range = frequency range = 25–120 kHz, fast Fourier transform
size = 512, overlap = 50%, time resolution = 1.024 ms, frequency
resolution = 488.2 Hz) using a previously published protocol75.

ClinVar data. The ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar) is a
freely accessible, public archive that catalogs relationships among human variants
and phenotypes with supporting evidence. Information for this study was collected
by searching for missense variants in UBE3A. For each variant, the resulting
protein change, associated conditions, clinical signiﬁcance, and accession number
was recorded. In addition, de-identiﬁed evidence details were recorded if present in
the database. For variants without evidence details, the submitting entity was
contacted for additional information.

Statistical analysis. Statistical analysis was performed using GraphPad Prism
7 software and SPSS v27 software for mouse behavior analysis. Statistical treatments for each experiment are listed below:
Figure 1d. One-sample t-test (two-tailed) with Benjamini–Hochberg multiple
comparisons correction (false discovery rate = 0.05). BAR responses were
normalized to WT UBE3A and tested for deviance from a theoretical mean value of
100. Individual p values are shown in Table S1. *p < 0.05, **p < 0.005, *p < 0.0005.
Figure 2a. One-sample t-test (two-tailed) with Benjamini–Hochberg multiple
comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
***p < 0.0005.
Figure 2f. One-sample t-test (two-tailed) with Benjamini–Hochberg multiple
comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
****p < 0.0005.
Figure 3b, c. One-sample t-test (two-tailed) with Benjamini–Hochberg multiple
comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
****p < 0.0005.

NATURE COMMUNICATIONS | (2021)12:6809 | https://doi.org/10.1038/s41467-021-27156-0 | www.nature.com/naturecommunications

13

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27156-0

Figure 5a. One-sample t-test (two-tailed) with Benjamini–Hochberg multiple
comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
***p < 0.0005.
Figure 5f. Tukey’s multiple comparison test detected a signiﬁcant interaction
between WT UBE3A × Q588E: q = 8.580, p < 0.001, and between WT
UBE3A × Q588R: q = 7.004, p < 0.001.
Figure 6c, d. Pearson Chi-square test, exact signiﬁcance (two-sided). *p < 0.05,
**p < 0.005, ***p < 0.0005.
Figure 6e, f. Mann–Whitney U-test, exact signiﬁcance (two-tailed). *p < 0.05,
**p < 0.005, ***p < 0.0005.
Figure 6h–k. Mann–Whitney U-test, exact signiﬁcance (two-tailed). *p < 0.05,
**p < 0.005, ***p < 0.0005.
Figure 6l. Repeated measures ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.
Figure 6m. Univariate linear mixed model. *p < 0.05, **p < 0.005,
***p < 0.0005.
Supplementary Fig. 1b. One-sample t-test (two-tailed) with Benjamini–Hochberg
multiple comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
***p < 0.0005.
Supplementary Fig. 2b. One-sample t-test (two-tailed) with Bonferroni multiple
comparisons correction (critical vale = 0.05). Mutant enzyme protein levels were
normalized to WT UBE3A and tested for deviance from a theoretical mean
abundance level of 100. *p < 0.05, **p < 0.005.
Supplementary Fig. 2e. One-sample t-test (two-tailed) with Bonferroni multiple
comparisons correction (critical value = 0.05). RING1B protein levels for each
UBE3A mutant-transfected sample was normalized to WT UBE3A and tested for
deviance from a theoretical mean abundance level of 100. *p < 0.05, **p < 0.005.
Supplementary Fig. 3d. One-sample t-test (two-tailed) with Benjamini–Hochberg
multiple comparisons correction (false discovery rate = 0.05). *p < 0.05, **p < 0.005,
***p < 0.0005.
Supplementary Fig. 5c, f. Mann–Whitney U-test, exact signiﬁcance (two-tailed).
*p < 0.05, **p < 0.005, ***p < 0.0005.
Supplementary Fig. 5g–l. Univariate linear mixed model. *p < 0.05, **p < 0.005,
***p < 0.0005.
All behavioral statistical analyses were performed in SPSS (v.27). ANOVA
assumption of normality was assessed by using the Shapiro–Wilks test and manual
assessment of the z-score histogram plot outputs. Mice that had a value greater
than 3.29 standard deviations above the mean were deemed inﬂuential outliers and
were removed from analysis. ANOVA assumption of equal variances was assessed
with the Levene’s test. For all reported behavioral tests which were found to violate
the assumptions of ANOVA, non-parametric tests were performed. Chi-square
goodness of ﬁt tests was used to assess associations between categorical variables.
For tests performed across multiple ages, the linear mixed model was used to
account for repeated measures.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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